TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer.
Grote I, Bartels S, Kandt L, Bollmann L, Christgen H, Gronewold M, Raap M, Lehmann U, Gluz O, Nitz U, Kuemmel S, Zu Eulenburg C, Braun M, Aktas B, Grischke EM, Schumacher C, Luedtke-Heckenkamp K, Kates R, Wuerstlein R, Graeser M, Harbeck N, Christgen M, Kreipe H.
Grote I, et al. Among authors: schumacher c.
Cancer Med. 2021 Dec;10(23):8581-8594. doi: 10.1002/cam4.4376. Epub 2021 Nov 14.
Cancer Med. 2021.
PMID: 34779146
Free PMC article.
METHODS: In this study, 622 estrogen receptor-expressing breast cancer cases treated with short-term preoperative endocrine therapy (pET) from the WSG-ADAPT trial (NCT01779206) were analyzed for genetic alterations associated with impaired endocrine proliferative response …
METHODS: In this study, 622 estrogen receptor-expressing breast cancer cases treated with short-term preoperative endocrine therapy ( …